Skip to main content

What the FDA labels say about taking them together

Phenobarbital and trabectedin

Trabectedin's FDA label (Yondelis) of January 6, 2026 names phenobarbital in its drug interactions section; the phenobarbital labels PlainMeds reads (2) do not name trabectedin. The trabectedin label: “Avoid using strong CYP3A inducers in patients taking YONDELIS.”

Check it at the source: the phenobarbital FDA label on DailyMed (effective August 27, 2026); the trabectedin FDA label on DailyMed (effective June 29, 2026, Apotex Corp.).

What does the phenobarbital label say about trabectedin?

Phenobarbital's label (effective August 27, 2026) and its 1 other brand-application label do not name trabectedin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Phenobarbital), Chartwell RX, LLC, effective August 27, 2026 (SPL set 74428144-fb24-40a5-a670-3b876e2d116c), via openFDA; the full label on DailyMed

What does the trabectedin label say about phenobarbital?

Yondelis label (Janssen Products, LP, January 6, 2026), drug interactions

Avoid using strong CYP3A inducers (e.g., rifampin, phenobarbital, St. John's wort) in patients taking YONDELIS [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (Yondelis, NDA207953), Janssen Products, LP, effective January 6, 2026 (SPL set 472bd78e-be17-4b9d-90f4-9482c3aec9ff), via openFDA

Source: FDA drug label (EVDI), Apotex Corp., effective June 29, 2026 (SPL set c1d50f5c-4202-27f3-4798-a9708114ddea), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Phenobarbital generic labelers
0Trabectedin generic labelers
PhenobarbitalTrabectedin
Labeled forSeizures and epilepsyn/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.213 per tablet 100 mg tabletn/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?